Alan E. Dow
Corporate Officer/Principal chez COMPLETE GENOMICS, INC.
Profil
Alan E.
Dow is currently the VP-Intellectual Property & legal Affairs at Complete Genomics, Inc. Previously, he worked as the Vice President & General Counsel at Vical, Inc. from 2001 to 2004, and as an Attorney at Acuity Law Group from 2004 to 2008.
Dr. Dow holds a doctorate degree from Harvard University, a graduate degree from Stanford University, and an undergraduate degree from the University of Maine.
Postes actifs de Alan E. Dow
| Sociétés | Poste | Début |
|---|---|---|
| COMPLETE GENOMICS, INC. | Corporate Officer/Principal | 01/09/2008 |
Anciens postes connus de Alan E. Dow
| Sociétés | Poste | Fin |
|---|---|---|
| Acuity Law Group | Corporate Officer/Principal | 01/09/2008 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Conseiller Juridique Général | 01/07/2004 |
Formation de Alan E. Dow
| Harvard University | Doctorate Degree |
| Stanford University | Graduate Degree |
| University of Maine | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Complete Genomics, Inc.
 Complete Genomics, Inc. BiotechnologyHealth Technology Complete Genomics, Inc. develops and markets DNA sequencing technology. It provides complete genomics analysis platform, which combines its proprietary human genome sequencing technology with the company's advanced informatics and data management software. The firm offers innovative, end-to-end, outsourced service model to the customers with data. The company was founded by Clifford A. Reid, Radoje T. Drmanac, David Smith and Robert John Curson in 2006 and is headquartered in San Jose, CA. | Health Technology |
| Acuity Law Group |